ClinicalTrials.Veeva

Menu
I

Investigate MD | Scottsdale, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3009104
STP705
Baricitinib
MT10109L
RIST4721
Risankizumab
Clascoterone
Etrasimod
Sofpironium Bromide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials
Locations recently updated

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution
Locations recently updated

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Lilly logo
P
S
AbbVie logo
Amgen logo
A
B
C
DermBiont logo
Medytox logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems